HR Execs on the Move

Cerus

www.cerus.com

 
Cerus Corporation is dedicated solely to safeguarding the world`s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.cerus.com
  • 1220 Concord Avenue
    Concord, CA USA 94520
  • Phone: 925.288.6000

Executives

Name Title Contact Details
Melody Holtan
 Vice President, Product Management & Blood Center Services Profile
Daniel Church
 Sr. Director, Device Engineering, R&D Profile
Alicia Goodman
 Chief Human Resources Officer Profile

Similar Companies

Takeda Oncology

Takeda Oncology,, is a biopharmaceutical company based in Cambridge, Massachusetts.

Earli

Earli has been funded by Andreessen Horowitz`s Bio Fund, Khosla, Perceptive Advisors, Casdin Capital, Sands Capital, Marc Benioff, Menlo Ventures, ZhenFund. Earli is based in the West Coast`s prime biotech hub in South San Francisco.

Synsorb Biotech

Synsorb Biotech Inc. is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Bamboo Therapeutics

Bamboo was formed to advance the work of Dr. Richard Jude Samulski, the Director of the Gene Therapy Center at the University of North Carolina (UNC), from the laboratory into human clinical trials where it could meet the requirements for drug approval. Dr. Samulski is a pioneer in the field of gene therapy. Over thirty (30) years ago, Dr. Samulski was the first person to realize the potential to use the adeno-associated virus (AAV) as a vehicle to replace a defective gene with a healthy gene. Since that time, he has re-engineered the naturally occurring virus to target delivery to certain tissues, de-target other tissues, and improve its safety. This has resulted in over twenty (20) patents related to the use of AAV for therapeutic uses. Dr. Samulski continues to lead innovation in the field of vector optimization and AAV re-engineering.

Barc USA

Barc USA is a New Hyde Park, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.